

Resource Summary Report

Generated by [RRID](#) on Aug 30, 2026

SW620

RRID:CVCL_0547

Type: Cell Line

Proper Citation

RRID:CVCL_0547

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0547

Proper Citation: RRID:CVCL_0547

Description: Cell line SW620 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Colon adenocarcinoma

Defining Citation: [PMID:286328](#), [PMID:288927](#), [PMID:327080](#), [PMID:833871](#), [PMID:924690](#), [PMID:1000501](#), [PMID:2041050](#), [PMID:3335022](#), [PMID:3518877](#), [PMID:6582512](#), [PMID:7972006](#), [PMID:9023415](#), [PMID:9178645](#), [PMID:9290701](#), [PMID:9294210](#), [PMID:9331090](#), [PMID:10700174](#), [PMID:10773689](#), [PMID:11113861](#), [PMID:11226274](#), [PMID:11414198](#), [PMID:11416159](#), [PMID:12068308](#), [PMID:12107847](#), [PMID:15748285](#), [PMID:16854228](#), [PMID:17088437](#), [PMID:18258742](#), [PMID:19188929](#), [PMID:19372543](#), [PMID:19927377](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20570890](#), [PMID:20606684](#), [PMID:21912889](#), [PMID:22068913](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22628656](#), [PMID:23272949](#), [PMID:23631600](#), [PMID:23856246](#), [PMID:23932154](#), [PMID:23933261](#), [PMID:24042735](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:24755471](#), [PMID:24840470](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25926053](#), [PMID:25944804](#), [PMID:26537799](#), [PMID:26589293](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27470641](#), [PMID:27807467](#), [PMID:27987026](#), [PMID:28196595](#), [PMID:28683746](#), [PMID:28854368](#), [PMID:29101300](#), [PMID:29131639](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31733513](#), [PMID:31978347](#), [PMID:32172478](#), [PMID:35839778](#), [PMID:36648961](#), [PMID:38861359](#)

Comments: Population: Caucasian., From: Scott and White Clinic; Temple; USA., Part of: NCI-60 cancer cell line panel., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AstraZeneca Colorectal cell line (AZCL)

panel.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SW620

Synonyms: SW-620, SW_620, SW 620, SW.620

Cross References: BTO:BTO_0000675, CLO:CLO_0009196, CLO:CLO_0009221, EFO:EFO_0002368, MCCL:MCC:0000448, CLDB:cl4443, CLDB:cl4444, CLDB:cl4969, AddexBio:C0009002/68, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CCL-227, BCRC:60343, BioGRID_ORCS_Cell_line:361, BioSample:SAMN03481108, BioSample:SAMN05292430, BioSample:SAMN07709977, BioSample:SAMN07709978, BioSample:SAMN07709979, BioSample:SAMN07709980, BioSample:SAMN07709981, BioSample:SAMN07709982, BioSample:SAMN07709983, BioSample:SAMN10988250, cancercellines:CVCL_0547, CCRID:1101HUM-PUMC000207, CCRID:3101HUMTCHu101, Cell_Model_Passport:SIDM00841, ChEMBL-Cells:ChEMBL3307944, ChEMBL-Targets:ChEMBL612262, CLS:300466, ColonAtlas:SW620, Cosmic:719676, Cosmic:724849, Cosmic:873706, Cosmic:875294, Cosmic:875900, Cosmic:876720, Cosmic:887243, Cosmic:889525, Cosmic:897460, Cosmic:905962, Cosmic:934561, Cosmic:948828, Cosmic:974248, Cosmic:983733, Cosmic:986020, Cosmic:990304, Cosmic:1071889, Cosmic:1092640, Cosmic:1122333, Cosmic:1154646, Cosmic:1175845, Cosmic:1176590, Cosmic:1183768, Cosmic:1184083, Cosmic:1187324, Cosmic:1219446, Cosmic:1223150, Cosmic:1305357, Cosmic:1310936, Cosmic:1312341, Cosmic:1466823, Cosmic:1479589, Cosmic:1524325, Cosmic:1552181, Cosmic:1609505, Cosmic:1676751, Cosmic:1708397, Cosmic:1995654, Cosmic:1998483, Cosmic:2156943, Cosmic:2302019, Cosmic:2389570, Cosmic:2668250, Cosmic:2727483, Cosmic:2760070, Cosmic:2823493, Cosmic-CLP:905962, DepMap:ACH-000651, ECACC:87051203, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:905962, GEO:GSM2107, GEO:GSM50192, GEO:GSM50256, GEO:GSM206553, GEO:GSM274773, GEO:GSM274774, GEO:GSM513819, GEO:GSM513867, GEO:GSM514313, GEO:GSM514314, GEO:GSM741270, GEO:GSM743447, GEO:GSM750800, GEO:GSM784023, GEO:GSM799335, GEO:GSM799398, GEO:GSM847163, GEO:GSM887677, GEO:GSM888769, GEO:GSM1006236, GEO:GSM1006237, GEO:GSM1006238, GEO:GSM1153405, GEO:GSM1178644, GEO:GSM1178645, GEO:GSM1178646, GEO:GSM1181305, GEO:GSM1181343, GEO:GSM1346892, GEO:GSM1374933, GEO:GSM1374934, GEO:GSM1374935, GEO:GSM1448212, GEO:GSM1862127, GEO:GSM1862128, GEO:GSM1862129, GEO:GSM2124652, GEO:GSM2299789, GEO:GSM2550017, GEO:GSM3591769, IARC_TP53:20, ICLC:HTL99015, IGRhCellID:SW620, KCB:KCB 2011098YJ, KCLB:10227, KCLB:60068, LiGeA:CCLE_536, LINCS_HMS:50047, LINCS_LDP:LCL-1157, Lonza:543, MetaboLights:MTBLS227, NCI-DTP:SW-620, PharmacDB:SW620_1541_2019, PRIDE:PXD000089, PRIDE:PXD003539, PRIDE:PXD003708, PRIDE:PXD004079, PRIDE:PXD005235, PRIDE:PXD005354, PRIDE:PXD005355, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD006662, PRIDE:PXD030304, PRIDE:PXD037651, Progenetix:CVCL_0547, PubChem_Cell_line:CVCL_0547, SKY/M-FISH/CGH:2806, SKY/M-FISH/CGH:5075, Wikidata:Q28519412

ID: CVCL_0547

Record Creation Time: 20220427T221615+0000

Record Last Update: 20260830T000042+0000

Ratings and Alerts

No rating or validation information has been found for SW620.

No alerts have been found for SW620.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 1616 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Liu X, et al. (2026) Role of Ca²⁺-Dependent Epithelial-Mesenchymal Transition in Malignant Progression of Colorectal Cancer: Special Focus on REG I^{??}/EDNRB. Cancer medicine, 15(4), e71754.

Zhang Y, et al. (2026) Nigakinone enhances FXR expression to synergize with irinotecan in suppressing colorectal cancer cells and xenografts. Biochemical pharmacology, 249, 117904.

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. Cell, 189(10), 2898.

Koo TY, et al. (2026) Protocol to identify covalent inhibitors targeting RhoA Cys16. STAR protocols, 7(2), 104494.

Beardsley JM, et al. (2026) Colorectal cancer-derived FGF19 is a metabolically active serum biomarker that exerts enteroendocrine effects on mouse liver. Molecular oncology, 20(6), 1494.

Hu X, et al. (2026) Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. Cell reports, 45(2), 116882.

Wang J, et al. (2026) Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers. Cell reports. Medicine, 7(2), 102577.

Radloff HS, et al. (2026) A single-cell derived spheroid approach to dissect intratumoural heterogeneity in colorectal cancer: cell lines show changes in proteomes and therapeutic response to 5-FU. Journal of cancer research and clinical oncology, 152(1), 43.

Fu D, et al. (2026) ETV4 Promotes Colorectal Cancer Progression by Reprogramming Asparagine Metabolism to Remodel the Stromal Microenvironment. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(26), e16557.

Qing S, et al. (2026) Folate promotes colorectal cancer progression by impairing CD8+ T cell function and recruitment via SLC19A1/p-AKT/NOTCH1 axis and CCL5 downregulation. *Journal of translational medicine*, 24(1).

Veltsista PD, et al. (2026) Non-Temperature-Induced Antitumor Effects of Amplitude-Modulated Radiofrequency: Molecular and Functional Synergies with Radiotherapy. *Cancers*, 18(10).

Menadi S, et al. (2026) Synergistic Anticancer Effects of *Akkermansia muciniphila* Combined With 5-Fluorouracil Through BAX/BCL2 Dependent Apoptosis in Colorectal Cancer Cells. *Cell biochemistry and function*, 44(5), e70234.

Zhan W, et al. (2026) Cathepsin-D-mediated MHC class I degradation contributes to immune evasion in colorectal cancer. *Cell reports. Medicine*, 102534.

Huang M, et al. (2026) KRT81 promotes metastasis of colorectal cancer by acting as a protein scaffold for ezrin. *Oncogene*, 45(3), 459.

Hmone NY, et al. (2026) Discovery of novel coumarin-containing triazolo[1,5-a]pyrimidine derivatives as potent ABCB1 inhibitor for modulation of multidrug resistance. *Journal of enzyme inhibition and medicinal chemistry*, 41(1), 2629074.

Li Z, et al. (2026) Engineered pistol ribozymes selectively target KRAS G12V with enhanced efficacy by capping modification. *Cell chemical biology*, 33(5), 671.

Ochtrop P, et al. (2026) Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates. *Nature communications*, 17(1), 759.

Wang P, et al. (2026) Thimerosal Inhibits Tumor Malignant Progression through Direct Action and Enhancing the Efficacy of PD-1-Based Immunotherapy. *Oncology research*, 34(2), 20.

Gao J, et al. (2026) AURKA-mediated destabilization of SACS3 drives ferroptosis evasion via 7-dehydrocholesterol biosynthesis in colorectal cancer. *Cell death & disease*, 17(1).

Chen K, et al. (2026) Amino acid supplementation enhances in vivo efficacy of lipid nanoparticle-mediated mRNA delivery in preclinical models. *Science translational medicine*, 18(840), eadx4097.